NasdaqGS - Nasdaq Real Time Price • USD
Puma Biotechnology, Inc. (PBYI)
As of 12:10 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.22 | 0.03 | 0.26 | 0.17 |
| Low Estimate | -0.23 | -0.07 | 0.23 | -0.07 |
| High Estimate | -0.21 | 0.11 | 0.3 | 0.48 |
| Year Ago EPS | 0.03 | 0.05 | 0.45 | 0.26 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | 41.05M | 57.3M | 219.23M | 217.03M |
| Low Estimate | 40.5M | 56.6M | 216M | 186M |
| High Estimate | 41.6M | 58M | 221.5M | 235.1M |
| Year Ago Sales | 52.77M | 54.6M | 235.6M | 219.23M |
| Sales Growth (year/est) | -22.20% | 4.90% | -6.90% | -1.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.07 | 0.01 | 0.08 | 0.3 |
| EPS Actual | 0.03 | 0.05 | 0.12 | 0.26 |
| Difference | 0.1 | 0.04 | 0.04 | -0.04 |
| Surprise % | 142.90% | 400.00% | 50.00% | -13.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.22 | 0.03 | 0.26 | 0.17 |
| 7 Days Ago | -0.22 | 0.03 | 0.26 | 0.17 |
| 30 Days Ago | -0.22 | 0.03 | 0.26 | 0.17 |
| 60 Days Ago | 0 | 0.07 | 0.3 | 0.33 |
| 90 Days Ago | 0 | 0.07 | 0.3 | 0.22 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | PBYI | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -833.30% | -- | -- | 0.80% |
| Next Qtr. | -40.00% | -- | -- | 9.60% |
| Current Year | -42.20% | -- | -- | 4.50% |
| Next Year | -34.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 232.50% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/1/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/13/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/20/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/4/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/5/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 5/5/2023 |
Related Tickers
LYRA Lyra Therapeutics, Inc.
5.45
+1.11%
KPTI Karyopharm Therapeutics Inc.
1.2500
-2.34%
MGTX MeiraGTx Holdings plc
5.01
0.00%
KURA Kura Oncology, Inc.
17.19
-2.77%
CTMX CytomX Therapeutics, Inc.
1.7200
-0.58%
VYGR Voyager Therapeutics, Inc.
7.47
-1.06%
ADMA ADMA Biologics, Inc.
6.11
-1.45%
SYRS Syros Pharmaceuticals, Inc.
4.5800
-2.97%
AGIO Agios Pharmaceuticals, Inc.
29.85
+1.43%
TSVT 2seventy bio, Inc.
4.5550
-1.83%